Lifeboat Foundation

The night sky has always played a crucial role in navigation, from early ocean crossings to modern GPS. Besides stars, the United States Navy uses quasars as beacons. Quasars are distant galaxies with supermassive black holes, surrounded by brilliantly hot disks of swirling gas that can blast off jets of material.

Following up on the groundbreaking 2020 discovery of newborn jets in a number of quasars, aspiring naval officer Olivia Achenbach of the United States Naval Academy has used NASA’s Hubble Space Telescope to reveal surprising properties of one of them, quasar J0742+2704.

“The biggest surprise was seeing the distinct spiral shape in the Hubble Space Telescope images. At first I was worried I had made an error,” said Achenbach, who made the discovery during the course of a four-week internship.

More than half of cancer deaths involve cancers that have no recommended screening tests, including highly deadly cancers like ovarian and pancreatic cancer.¹ Multi-cancer detection (MCD) tests are a new type of blood test designed to detect multiple cancers. Despite limited evidence on their benefit, some MCD tests are currently available to the public as cancer screening tools and many more are in development.

Research is underway to try to address the many unanswered questions about cancer screening with MCD tests. To learn more about the uncertainties related to public and clinician perceptions of MCD tests, program officials at the National Cancer Institute (NCI), led by Goli Samimi, Ph.D., M.P.H., Program Director in the Breast and Gynecologic Cancer Research Group in the Division of Cancer Prevention (DCP), decided to ask them directly. NCI facilitated focus groups with practicing primary care physicians (PCPs) and laypersons to learn about their awareness and knowledge of MCD tests and their thoughts on the benefits, harms, uncertainties, and acceptability of using this emerging technology.

“More rigorous data on MCD tests is needed to inform the development of national guidelines for use as cancer screening tools,” said Lori Minasian, M.D., FACP, Deputy Director, DCP, NCI. “We need to know more about people in the community who will be consumers of MCD tests and the professionals responsible for administering tests, interpreting results, and determining next steps.”

[](https://youtu.be/SWXgWLv4ndw)Subscribe!

0:00 Bryan Johnson is Anime Villain Orochimaru.
1:54 The Impact of Mormonism.
2:54 The Mission Trip that Changed Everything.
3:45 Training Arc — To Make Millions.
4:08 Falling Apart.
6:34 Slowly Picking Himself Back Up — $300 Million.
7:33 Finding Freedom in Warehouse Party in Brooklyn.
8:51 Finding His New Goal.
9:25 The Blueprint Protocol.
11:36 The True Goal — Super Intelligence.
12:57 Aligning Humanity with ASI
13:38 Building a new religion and becoming God.
15:23 Letting AI Control Our Decisions.
17:00 The First IRL Anime Villain.
18:30 Overall Thoughts.

Continue reading “Bryan Johnson’s SHOCKING True Goal (it’s not age reversal): The Story of The 1st IRL Anime Villain” »

Join us on Patreon! https://www.patreon.com/MichaelLustgartenPhD

Discount Links/Affiliates:
Blood testing (where I get the majority of my labs): https://www.ultalabtests.com/partners/michaellustgarten.

Continue reading “Immune Cell Dysfunction Causes Aging: Matt Yousefzadeh, PhD” »

In a groundbreaking effort to enhance lunar exploration, NASA

NASA, the National Aeronautics and Space Administration, is the United States government agency responsible for the nation’s civilian space program and for aeronautics and aerospace research. Established in 1958 by the National Aeronautics and Space Act, NASA has led the U.S. in space exploration efforts, including the Apollo moon-landing missions, the Skylab space station, and the Space Shuttle program.

Anduril, a technology start-up that designs autonomous systems and weapons for government agencies and the military, plans to build a $1 billion factory in Columbus, Ohio, the company said on Thursday.

It said the factory, called Arsenal-1 and described as a “hyperscale” plant, would bring more than 4,000 job to Ohio and eventually produce tens of thousands of autonomous systems and weapons each year.

“We will be creating with our partners in Ohio something that does not currently exist” at such a scale, Anduril’s chief strategy officer, Chris Brose, said in a briefing with reporters. The company has worked closely with state officials on the project and has secured tax breaks to locate it in Columbus.

In today’s AI news, François Chollet, an influential AI researcher, is launching a new startup that aims to build frontier AI systems with novel designs. The startup, Ndea, will consist of an AI research and science lab. It’s looking to “develop and operationalize” AGI. It’s a goalpost for many AI companies …

In other advancements, San Francisco-based Luma released Ray2, its newest video AI generation model, available now through its Dream Machine website and mobile apps for paying subscribers (to start). The model offers “fast, natural coherent motion and physics,” according to CEO Amit Jain.

And, Microsoft has been positioning Copilot as the “UI for AI.” Now, as the next step in this work, it is launching Microsoft 365 Copilot Chat — a rebranded version of its free AI chat experience for businesses, enhanced with agentic capabilities.

Continue reading “AI Researcher François Chollet Founds A New AI Lab Focused On AGI” »

The study introduces soft, conformable transistors embedded in a single organic material.

Researchers develop biocompatible implants that adapt to the body’s growth, paving the way for advanced neurological monitoring in children.

The utility of left atrial appendage occlusion (LAAO) as a therapy for stroke prevention in patients with nonvalvular atrial fibrillation (AFib) is the focus of a State-of-the-Art Review published Jan. 8 in JACC: Clinical Electrophysiology.

Jalaj Garg, MBBS, FACC, et al., discuss the procedure’s journey to becoming a mainstream approach for stroke prevention, advancements in LAAO devices over the past two decades, and domains requiring additional scientific inquiry. The authors describe the LAA as an “important therapeutic target” in treating patients with AFib, as the LAA is “the most common site for thrombus formation and an important source of non-pulmonary vein triggers.” They outline the anatomy, physiology and clinical relevance of the LAA along with the evolution of LAA exclusion techniques and devices overtime.

Acknowledging the major advancements in LAAO device technology and clinical benefits, the authors note the ACC, American Heart Association and Heart Rhythm Society have “updated recommendations to Class 2a in patients with moderate to high risk for stroke or contraindications to long-term [oral anticoagulation (OAC)], with weak recommendations (Class 2b) in patients with moderate to high risk for stroke or reasonable to continue long-term OAC.”